| Digestive Organs / Gastrointestinal (GI)
|
|
Protocol#
|
Principal Investigator
|
Title
|
| UCI 07-02 |
Holcombe |
A multicenter randomize double-blind placebo controlled Phase III study of the efficacy of Xaliproden in preventing the neutroxity of oxaliplatin on the first-line treatment of patients with metastatic colorectal cancer treated with oxaliplatin/5-FU/LV. |
| UCI 05-20 |
Holcombe |
Resveratrol for Patients with Colon Cancer |
| UCI 98-20 |
Holcombe |
Investigation into the Molecular Events Involved in the
Development of Cancer |
| UCI 02-69 |
Nelson |
A Phase I Clinical Trial of GM-CSF Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma |
| UCI 03-11 |
Chang |
A Randomized, Phase II, Study of TNFerade Biologic
with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer.
|
| UCI 05-25 |
Stamos |
Timing of Rectal Cancer Response to Chemoradiation |
| UCI 01-61 |
Imagawa |
A Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma
|
| UCI 04-05 |
Holcombe |
Investigation into the Molecular Causes of Colon and Rectal Cancers |
| UCI 03-15 |
McDougall |
Long Term Follow-up of Laparoscopic Renal Surgery |
| UCI 06-42 |
Chang |
Targeting Delivery of Inco VEX by EUS-Guided Fine-Needle Injection in Patients with Irresectable Pancreatic Cancer
|
| ZOO Z6041 |
Stamos |
A Phase II Trial of Neoadjuvant Chemoradiation and Local Excision for uT2uN0 Rectal Cancer
|
| SWOG 9444 |
Holcombe |
Gastrointestinal Tumor Repository Protocol
|
| SWOG S0600 |
Holcombe |
Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or w/o Bevacizumab (NSC-704865) as Second-Line Therapy for Pts with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX, or XELOX |
For additional information on open UCI clinical trials please call toll-free 1-877-UC-STUDY or email ucstudy@uci.edu.
